FRC
FRC Logo
Community
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Markets

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Company ProfileImmutep Limited
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
IMM.AX
Immutep Limited Stock AnalysisComprehensive stock analysis for Immutep Limited (IMM.AX) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisIMM.AX
IMM.AX
Immutep Limited
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
IMM.AX
  1. Home
  2. Stocks
  3. Immutep Limited

Immutep Limited

🇦🇺IMM.AX•ASX

Immutep Limited

🇦🇺IMM.AX•ASX

Your view on IMM.AX

Your view
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Immutep Limited

Industry
Biotechnology
Sector
Healthcare
CEO
Marc Voigt
Headquarters
Australia Square, Sydney, NSW, AU
Industry
Biotechnology
Sector
Healthcare
CEO
Marc Voigt
Headquarters
Australia Square, Sydney, NSW, AU
Description

Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia.

Its lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on LAG-3 immune control mechanism for the treatment of different types of cancers.

The company’s product pipeline also includes TACTI-004, which is in phase III clinical trial for the treatment of first line non-small cell lung cancer (1L NSCLC); TACTI-003, which is in phase IIb clinical trial to treat first line head and neck squamous cell carcinoma (HNSCC); INSIGHT-005 which is in phase I for metastatic urothelial carcinoma; TACTI-002, which in phase II trial for the treatment NSCLC and HNSCC; AIPAC-003, which is in phase II/III clinical trial to treat metatastic breast cancer; and EFTISARC-NEO, which is in phase II clinical trial for the treatment of soft tissue sarcoma.

It also develops INSIGHT-003, which is in phase I trial 1L non squamous NSCL; INSIGHT-005 that is in phase I to treat metastatic urothelial cancer; IMP761, which is in phase I Trial to treat autoimmune disease; IMP731 for oncology and autoimmune diseases; and LAG525.

Immutep has collaboration with Merck & Co., Inc., EOC Pharma, Novartis, and Laboratory Corporation of America Holdings. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is based in Sydney, Australia.

Financial Data

Stock Data

Price chart, volume, and trading data.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

About this section

Valuation, profitability, liquidity and leverage ratios for Immutep Limited. Starting points for Immutep Limited: EPS -AUD 0.05, beta 2.22 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

About this section

Dividend history, yield and payout sustainability for Immutep Limited. Immutep Limited does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

About this section

Reported vs. expected earnings history for Immutep Limited. Trailing twelve-month EPS for Immutep Limited stands at -AUD 0.05. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Wall Street Analyst Estimates

Analysts' price targets, ratings, and revenue and EPS estimates.

Wall Street analysts· not FRC research
Nov 20, 2026

Buy

Analyst ratings

3 ratings
  • Strong Buy0
  • Buy3
  • Hold0
  • Sell0
  • Strong Sell0
More →

Earnings per share estimates

Per shareThis quarterJun 2018Next quarterJun 2019This yearYear to Jun 2027Next yearYear to Jun 2028
Average estimate−AUD 0.02−AUD 0.02−AUD 0.01−AUD 0.01
Lowest estimate−AUD 0.02−AUD 0.02−AUD 0.02−AUD 0.01
Highest estimate−AUD 0.02−AUD 0.02−AUD 0.01−AUD 0.01
Number of analysts2333
A year ago——−AUD 0.051—
Growth vs a year ago————

1The year-ago figure includes one-time items, so growth is not shown.

Revenue estimates

TotalThis quarterJun 2018Next quarterJun 2019This yearYear to Jun 2027Next yearYear to Jun 2028
Average estimateAUD 1.70MAUD 9.62MAUD 3.88MAUD 2.00M
Lowest estimateAUD 1.62MAUD 7.81MAUD 3.88MAUD 2.00M
Highest estimateAUD 1.70MAUD 11.12MAUD 3.88MAUD 2.00M
Number of analysts2311
A year ago——AUD 14.56M—
Growth vs a year ago——−73.4%—
Recent rating and target changes (4)

Financial Statements

Income statement, balance sheet, and cash flow statements.

About this section

Income statement, balance sheet and cash flow history for Immutep Limited. Immutep Limited has reported as a listed company since 1988. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Peers, the industry, and the funds that hold IMM.AX20 companies · 1 funds
Compare IMM.AX with its peers, side by sidePremiumRatios, margins, valuation and leverage of the peers below — one table, one glance.Open Comparable Analysis
Peer companies
TickerTypeCompanySectorIndustry
AYA.AXArtrya LimitedHealthcareMedical - Healthcare Information Services—
BOT.AXBotanix Pharmaceuticals LimitedHealthcareBiotechnology—
CUV.AXClinuvel Pharmaceuticals LimitedHealthcareBiotechnology—
DXB.AXDimerix LimitedHealthcareBiotechnology—
EBR.AXEBR Systems, Inc.HealthcareMedical - Devices—
IMR.AXImricor Medical Systems, Inc.HealthcareMedical - Specialties—
MYX.AXMayne Pharma Group LimitedHealthcareMedical - Pharmaceuticals—
OCC.AXOrthocell LimitedHealthcareBiotechnology—
More Biotechnology companies
TickerTypeCompanySectorExchangeMkt cap
PCVXVaxcyte, Inc.HealthcareNASDAQ$9.3B
PDSBPDS Biotechnology CorporationHealthcareNASDAQ$43.8M
PEPGPepGen Inc.HealthcareNASDAQ$265.3M
PFNDPathfinder Cell Therapy, Inc.HealthcareOTC$66,716
PGENPrecigen, Inc.HealthcareNASDAQ$1.5B
PHARPharming Group N.V.HealthcareNASDAQ$882.4M
PHATPhathom Pharmaceuticals, Inc.HealthcareNASDAQ$430.8M
PHGUFPharming Group N.V.HealthcareOTC$1.1B
PHIOPhio Pharmaceuticals Corp.HealthcareNASDAQ$8.6M
PHMMFPharma Mar, S.A.HealthcareOTC$1.5B
PHRM.CNPharmaTher Holdings Ltd.HealthcareCNQ$9.1M
PHRRFPharmaTher Holdings Ltd.HealthcareOTC$5.3M
ETFs holding Immutep Limited
TickerFundFund assets% of the fund
AVDSAvantis International Small Cap Equity ETF$379M in assets—

Largest holders first, then the funds most concentrated in IMM.AX.

Open Comparable Analysis
Ownership & News

News

Latest headlines and market coverage.

About this section

Latest headlines and company announcements for Immutep Limited. Coverage tracks Immutep Limited within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Discussion

Comments

Comments and replies from FRC members about this company.

No comments yet

Be the first to ask a question or say what you make of Immutep Limited.

IMM.AX AnalysisFair
Past
1
Growth
5
Health
5
Profit
1
Value
1